Metastatic Breast Cancer Clinical Trial
Official title:
A Phase 3 Asian Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (MBC) Who Have Failed at Least 2 Prior Chemotherapy Regimens
Verified date | June 2024 |
Source | Gilead Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy regimens.
Status | Active, not recruiting |
Enrollment | 331 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Female or male individuals aged =18 years at the time of signing the informed consent form - Documented evidence of hormone receptor-positive HER2-negative (HR+/HER2-) MBC confirmed - Refractory to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for MBC - Should have been previously treated with at least 1 taxane in any setting, at least 1 prior anticancer hormonal treatment in any setting - Eligible for one of the chemotherapy options listed in the TPC arm - Documented radiographic disease progression after the most recent therapy - Measurable disease by CT or MRI in accordance with RECIST v 1.1, bone-only disease is not measurable and is not permitted. - Adequate bone marrow function, hepatic and renal function - Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta human chorionic gonadotropin [ß-hCG] Key Exclusion Criteria: - Previous treatment with Topoisomerase 1 Inhibitors as a free form or as other formulations - Individuals who have known brain metastases. - Have an active second malignancy within 3 years prior to providing informed consent - Individuals with active hepatitis B virus (HBV), or hepatitis C virus infection (measurable viral RNA load with polymerase chain reaction). - Active serious infection requiring systemic antibiotic use within 7 days before Cycle1 Day 1. - Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. - Known hypersensitivity or intolerance to either of the study treatments or any of the excipients. Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
China | Cancer Hospital Chinese Academy of Medical Science | Beijing | |
China | Chinese PLA General Hospital | Beijing | |
China | Peking University People's Hospital | Beijing | |
China | Jilin Cancer Hospital | Changchun | |
China | The First Hospital of Jilin University | Changchun | |
China | Chongqing University Cancer Hospital | Chengdu | |
China | West China Hospital, Sichuan University | Chengdu | |
China | Fujian Medical University Union Hospital | Fuzhou | |
China | Guangdong Provincial People's Hospital | Guangzhou | |
China | Sun Yat Sen Memorial Hospital of Sun Yat sen University | Guangzhou | |
China | Sun Yat-sen University Cancer Center | Guangzhou | |
China | Sir Run run Shaw hospital Zhejiang University School of Medicine | Hangzhou | |
China | Zhejiang Cancer Hospital | Hangzhou | |
China | Anhui Provincial Hospital | Hefei | |
China | The second Hospital of Anhui Medical University | Hefei | |
China | Shandong Cancer Hospital | Jinan | |
China | Yunnan Cancer Hospital | Kunming | |
China | Linyi Cancer Hospital | Linyi | |
China | Jiangsu Province Hospital | Nanjing | |
China | Nanjing Drum Tower Hospital | Nanjing | |
China | Shanghai General Hospital | Shanghai | |
China | Tianjin Medical University Cancer Institute & Hospital | Tianjin | |
China | Affiliated Tumor Hospital of Xinjiang Medical University | Ürümqi | |
China | Hubei Cancer Hospital | Wuhan | |
China | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | |
China | The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | |
China | Henan Cancer Hospital | Zhengzhou | |
Korea, Republic of | Dong-A University Hospital | Busan | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Korea University Anam Hospital | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital Yonsei University Health System | Seoul | |
Korea, Republic of | Ajou University Hospital | Suwon | |
Taiwan | Changhua Christian Medical Foundation Changhua Christian Hospital | Changhua | |
Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | National Cheng Kung University Hospital | Tainan | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei | |
Taiwan | Tri-Service General Hospital | Taipei | |
Taiwan | Chang Gung Memorial Hospital, Linkou | Taoyuan |
Lead Sponsor | Collaborator |
---|---|
Gilead Sciences |
China, Korea, Republic of, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival (PFS) | PFS is defined as from the date of randomization until the date of disease progression (PD) or death, whichever occurs earlier. Disease progression will be determined according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) by Independent Reviewing Committee (IRC). | Up to 3 years | |
Secondary | Overall Survival (OS) | OS is defined as from the date of randomization to death from any cause. | Up to 4 years | |
Secondary | Objective Response Rate (ORR) by IRC | ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR). | Up to 4 years | |
Secondary | Duration of Response (DOR) by IRC | DOR is defined as from the date of first onset of tumor response (CR or PR) to PD or death, whichever occurs earlier. | Up to 4 years | |
Secondary | Clinical Benefit Rate (CBR) by IRC | CBR is defined as best overall response of CR or PR or durable stable disease (SD) (duration of SD = 6 months after randomization). | Up to 4 years | |
Secondary | Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | First dose date up to 4 years plus 30 days | ||
Secondary | Percentage of Participants Experiencing Serious Adverse Events (SAEs) According to NCI CTCAE Version 5.0 | First dose date up to 4 years plus 30 days | ||
Secondary | Change From Baseline of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30, Version 3.0 (EORTC QLQ-C30) Score | The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) to assess 15 scales; 1 global health status/quality of life (QOL), 5 functional scales (physical, role, cognitive, emotional, and social), and 9 symptom/item scales(fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of function, a high score for the global health status/QOL represents a high QOL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. | Baseline, up to 4 years | |
Secondary | Change From Baseline of the European Quality of Life 5-Dimensions 5 Levels Instrument (EuroQOL EQ-5D-5L) Score | The EQ-5D-5L is an instrument for use as a measure of health outcome.The EQ-5D-5L consists of 2 sections: the EuroQoL (5 dimensions) (EQ-5D) descriptive system and the EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health. | Baseline, up to 4 years | |
Secondary | Percentage of Participants Experiencing Treatment-Emergent Adverse Events Assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE) | NCI PRO-CTCAE is a patient-reported item library used to evaluate symptomatic treatment-emergent adverse events in participants on cancer clinical trials. The items selected for this study include: decreased appetite, nausea, vomiting, constipation, diarrhea, abdominal pain, shortness of breath, hair loss, and fatigue. | Baseline, up to 4 years | |
Secondary | Pharmacokinetic (PK) Parameter: Cmax of Sacituzumab Govitecan-hziy and Free SN-38 | Cmax is defined as the maximum observed concentration of drug. | Up to 4 years | |
Secondary | PK Parameter: Tmax of of Sacituzumab Govitecan-hziy and Free SN-38 | Tmax is defined as the time to maximum drug concentration. | Up to 4 years | |
Secondary | PK Parameter: Ctrough of Sacituzumab Govitecan-hziy and Free SN-38 | Ctrough is defined as the concentration of drug at the end of the dosing interval. | Up to 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04872608 -
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02506556 -
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05534438 -
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03368729 -
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04103853 -
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Active, not recruiting |
NCT03147287 -
Palbociclib After CDK and Endocrine Therapy (PACE)
|
Phase 2 | |
Not yet recruiting |
NCT06062498 -
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04095390 -
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04432454 -
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
|
Phase 2 | |
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
Completed |
NCT02924883 -
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
|
Phase 2 | |
Completed |
NCT01942135 -
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
|
Phase 3 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT01401959 -
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT04720664 -
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
|
Phase 2 |